z-logo
open-access-imgOpen Access
Plasma 249 Ser p53 mutation in patients with hepatocellular carcinoma residing in a high risk area
Author(s) -
DongDong Lu,
XiRan Zhang
Publication year - 2003
Publication title -
journal of cellular and molecular medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.44
H-Index - 130
eISSN - 1582-4934
pISSN - 1582-1838
DOI - 10.1111/j.1582-4934.2003.tb00207.x
Subject(s) - transversion , hepatocellular carcinoma , exon , mutation , carcinoma , microbiology and biotechnology , restriction site , gene mutation , genomic dna , biology , gene , cancer research , medicine , genetics , restriction enzyme
Objective : To investigate plasma p53 mutation in hepatocellular carcinoma (HCC) patients from Qidong and to define its significance. Methods: Blood samples from 25 hepatocellular carcinoma patients, 20 cirrhotic patients and 30 healthy controls in Qidong area. DNA was extracted and purified from 200μl of plasma from each sample. The 249 Ser p53 mutation was detected by restriction digestion analysis and by direct sequencing of exon‐7 PCR products. Results: G→T transversion at the third base of 249 codon resulting in 249 Arg →249 Ser mutation in exon 7 of p53 gene were found in 11/25(44%) hepatocellular carcinoma cases, 4/20 (20%) cirrhotics, and 2/30 (7%) healthy controls (p<0.01). Conclusions: These data show that the 249 Ser p53 mutation in plasma is strongly associated with hepatocellular carcinoma patients in Qidong area and the mutation should be screened as a new early diagnostic marker for HCC.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom